The 7th Annual Biosimilars Conference
Hear from over 20 Expert Leaders in the Biosimilar Field
With over 15 new speakers confirmed for Informa's 2010 Biosimilars Conference, this year's event will be an unmissable opportunity to update your knowledge on this dynamic and important market with some of the field's best experts.
Highlights of Biosimilars 2010
- Explore the latest developments with biobetters and read more
- Revisit the EU Market. Learn what read more
- Discover recent developments with biosimilar mAbs. Hear from read more
- Update your knowledge on advancements in read more
- Analyse the strategies used by F Hoffmann- La Roche for read more
- Ascertain what the physician’s perception is read more
- Familiarise yourself with patent law strategies and read more
Expert Speaker Pannel
Expert Speaker Pannel
Dr Jay Siegel
Chief Biotechnology Officer
Johnson & Johnson
|
Mateja Urlep
Founder & CEO
TikhePharma
|
Richard Dicicco
Chairman
Harvest Moon Pharmaceuticals
|
Dr Christian Clauss
Senior Consultant
Hisut SA Ltd
|
Dr Anton Haselbeck
Head of New Technologies
Roche Pharma Research
|
Dr Anshuman Patwardhan
Senior Director
Dr Reddy's
|
Dr Keith Watson
Principle Consultant
PAREXEL
|
William Haddad
Chairman and CEO
Biogenerics
|
..
Media Partners
..
..
..
..
Sponsors
..
..
..
Where and When?
08 Jun 2010 - 09 Jun 2010
Pullman Hotel, Cologne, Germany
Speakers at Biosimilars 2010
Anshuman Patwardhan, Senior Director, Portfolio Strategy & Licensing, Biologic Division, Dr Reddy's Laboratories, India
Anne Cook, Quality Assessor, MHRA, UK
Robin Thorpe, HEAD - Biotherapeutics Group, NIBSC, UK
Jay Siegel, Chief Biotechnology Officer, Global Head, Regulatory Affairs, Pharmaceuticals Group, Johnson & Johnson, USA
Matthew Field, Protein Analytical Chemistry, Genentech, USA
Anton Haselbeck, Head of New Technologies, Roche Pharma Research,
Germany
Sven Kronenberg, Global Coordinator Biologics Safety, Non-Clinical Saftey, F. Hoffmann-La Roche Ltd, Switzerland
Richard Dicicco, Chairman, Harvest Moon Pharmaceuticals, USA
Keith Watson, Principal Consultant, Parexel Consulting, UK (Formerly MHRA)
Mateja Urlep, Founder & CEO, TikhePharma, (Formerly Sandoz), Slovenia
Cecil Nick, Vice President Biotechnology, PAREXEL, UK
William Haddad, Chairman and Chief Executive Officer, Biogenerics, USA
Stanley SS Hong, Senior Vice President, Head of Research & Development, Celltrion, Inc, South Korea
Michael Malecki, Director, Decision Resources, USA
Fernando de Mora, Consultant, Salupharma Biosimilars SA, Chairman, Dept. of Pharmacology, Therapeutics and Toxicology, Medical School, Universidad Autónoma de Barcelona, Spain
Liz Fuller, Director, Life Sciences, Wragge and Co., UK
Lorna Brazell, Partner Intellectual Property, Bird & Bird LLP, UK
Tuesday 8 June: Evening Seminar
Fast Followers, Differentiated Biosimilars, BioBetters or NBEs – Which Strategy is Best for Which Markets?
Gain an understanding of
-
how biobetters and differentiated biosimilars are
viable alternatives to biosimilars for regulated markets -
how copy biopharmaceuticals
can generate profits to sustain research for NBEs -
and how small molecules are threatening fast followers in regulated markets
Led by Richard Dicicco, Chairman, Harvest Moon Pharmaceuticals, USA
Sponsors
Poll
What area of the EU’s current regulatory framework on biosimilars is most in need of reform?
Reviews
"This biosimilars conference was Bio Better than others in this field"
"Very interesting two days covering several aspects (technical, regulatory, legal) of the biosimilar topic!"
"Interesting and informative"
